Intervacc (IVACC) Life Science Conference 2026 summary

Technology platform and product pipeline

• Proprietary recombinant fusion protein platform enables development of highly effective vaccines with strong immune responses and easy administration.

• Lead product Strangvac® targets strangles in horses, with a pipeline including Piggivac for S. suis in piglets.

• Solid portfolio includes fully owned and licensed products, with near-term milestones such as label changes, launches in France and Germany, and completion of regulatory trials.

• Strategic veterinary medicine portfolio in Scandinavia complements in-house vaccines.

Market opportunity and commercialization

• Strangvac® addresses a global market of ~60 million horses, with primary markets in Europe, US, and Oceania.

• If adopted as a standard, annual sales could reach 11 million doses in primary markets.

• Focus on key opinion leaders (KoLs) in Sweden and UK has driven increased adoption and guideline development.

• US market launch targeted for 2028, with ongoing pivotal studies and regulatory engagement.

Product efficacy and real-world data

• Strangvac® provides sustained antibody levels for 12 months and 94% protection after booster vaccination.

• Field studies show 90% protection in vaccinated horses during outbreaks, with low adverse event rates.

• Over 30,000 horses have received Strangvac® with no serious adverse events reported.